HIGHLIGHTS
- who: Artemisinin-based combination therapy et al. from the Axios International, Boulevard la Madeleine, Paris, France have published the article: Artemisinin-based combination therapy availability and use in the private sector of five AMFm phase 1 countries, in the Journal: (JOURNAL)
- what: The aim of this study was to assess anti-malarial stock and purchase patterns at private outlets in five AMFm Phase 1 countries in regard to three of the core AMFm goals: increase the affordability of QAACT increase the availability of QAACT and crowd out monotherapies and other substandard therapies. All forms of . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.